Sat.Sep 07, 2024 - Fri.Sep 13, 2024

article thumbnail

With another phase 3 win, Gilead races toward 2025 launch for long-acting PrEP drug

Fierce Pharma

Gilead Sciences is no stranger to making history in HIV. | In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.

329
329
article thumbnail

Rural Healthcare Goes Beyond Care: Targeting SDOH to Improve Health Outcomes

MedCity News

As poverty, food insecurity, inadequate housing, and complex comorbidities persist, it is essential that rural healthcare leaders have tools and systems in place to address the health of their neighbors. The post Rural Healthcare Goes Beyond Care: Targeting SDOH to Improve Health Outcomes appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Who’s winning in biotech’s tight market?

PharmaVoice

Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.

Marketing 262
article thumbnail

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Pharmaceutical Technology

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.

article thumbnail

State of AI in Sales & Marketing 2025

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

article thumbnail

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer

Fierce Pharma

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.

354
354
article thumbnail

These Are 2 of The Biggest Issues with Healthcare AI, According to an FDA Reviewer

MedCity News

As the FDA continues its work to ensure that AI is deployed safely within healthcare, there are a couple prevalent issues that frequently pop up, said Luke Ralston, one of the agency’s reviewers. The post These Are 2 of The Biggest Issues with Healthcare AI, According to an FDA Reviewer appeared first on MedCity News.

More Trending

article thumbnail

How To Shorten Your Sales Cycles With Anne Saulnier

Evolve Your Success

Anne Saulnier, the trailblazing CEO of Hex IQ, joins us to reveal how reimbursement data is revolutionizing healthcare sales. With her unique expertise in both marketing and enterprise software, Anne sheds light on the groundbreaking changes brought about by the 2020 law that mandates insurance companies to disclose negotiated rates. This newfound transparency empowers medical sales reps to showcase ROI compellingly, target the right customers, and accelerate their sales cycles.

Sales 130
article thumbnail

After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned

Fierce Pharma

After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.

325
325
article thumbnail

300+ Provider Organizations Urge Feds to Prevent Leaked DEA Rule From Going into Effect

MedCity News

More than 330 provider organizations signed letters this week urging the White House and Congress to extend a pandemic-era telehealth prescribing flexibility. Failure to extend this policy would cause millions of Americans to lose access to treatment, they argued. The post 300+ Provider Organizations Urge Feds to Prevent Leaked DEA Rule From Going into Effect appeared first on MedCity News.

321
321
article thumbnail

3 FDA approval dates to watch in the year’s final push

PharmaVoice

A handful of potential blockbusters are marching toward FDA review.

FDA 246
article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Augmented Reality: Transforming Surgical Planning And Navigation

Infuse Medical

With uses going beyond entertainment and into vital sectors like surgery, augmented reality (AR) is transforming the healthcare sector. AR gives surgeons better vision by overlaying digital data onto the physical world, therefore enabling them to execute difficult treatments with more confidence and accuracy. By 2024 there will be an estimated 1.7 billion mobile augmented reality (AR) users worldwide, a rise of 1.5 billion from the 200 million seen in 2015.

Doctors 130
article thumbnail

After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug

Fierce Pharma

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s Tecentriq Hybreza after manufacturing delays derailed the company's initia | The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq.

FDA 313
article thumbnail

The New Role of Engagement: Surfacing Insights at the Point of Care and Beyond

MedCity News

By surfacing conversational, behavioral, and environmental insights at the point of care — and enabling data-driven operational decisions — AI has the power to transform individual patient experiences and drive systemic improvements in care quality and efficiency. The post The New Role of Engagement: Surfacing Insights at the Point of Care and Beyond appeared first on MedCity News.

Patients 319
article thumbnail

A new way of determining a drug’s value — with health equity in mind

PharmaVoice

Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.

246
246
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Empowering Patients-The Role of Interactive Demonstrations in Medical Device Education

Infuse Medical

As the healthcare industry is moving forward to the latest technologies, interactive patient demonstrations are a must development needed so far. Of course, patient medical device education and counseling are to educate them about diseases, procedures, and the treatments followed. It is not only to educate but also to enhance compliance with medical treatment regimens.

Education 130
article thumbnail

ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide

Fierce Pharma

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. Yet company CEO Hervé Hoppenot views the antibody molecule not necessarily as a major revenue driver but as an aide to the company’s oncology pipeline.

312
312
article thumbnail

The Human Touch: Why Human Transcriptionists Still Outperform AI in Healthcare

MedCity News

While AI continues to advance, the healthcare industry requires a level of accuracy, understanding, and confidentiality that only well-trained human transcriptionists can consistently provide. The post The Human Touch: Why Human Transcriptionists Still Outperform AI in Healthcare appeared first on MedCity News.

article thumbnail

Why pharma should redefine ‘women’s health’

PharmaVoice

A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.

Pharma 246
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The Future of Medical Training: Harnessing VR and Emerging Technologies

Infuse Medical

The healthcare industry today stands as the first and the most crucial one among other sectors. The development and innovations for healthcare services are unlimited. But, the fact is the medical industry is growing at a faster pace with AI and VR technologies. Implementing emerging technologies for the future of medical training is most welcome. Do you imagine how it would be in the future?

Training 130
article thumbnail

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

Fierce Pharma

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation.

FDA 301
article thumbnail

SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition

MedCity News

Securities regulators say the role of Ipsen employee Dishant Gupta made him privy to details of the Epizyme acquisition. Gupta allegedly accumulated Epizyme shares while the deal was negotiated, then sold all of them hours after the transaction was announced. The post SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition appeared first on MedCity News.

Biopharma 316
article thumbnail

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

PharmaVoice

Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Medicine 245
article thumbnail

The GTM Intelligence Era: ZoomInfo 2025 Customer Impact Report

ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!

article thumbnail

Mastering Medical Proficiency: Crafting Competency-Based Training Programs in Healthcare

Infuse Medical

The demand for highly qualified individuals is never stronger in the fast-paced and always changing environment of healthcare. Competency-based training healthcare is a novel method emphasizing on the acquisition of the exact skills and information required for healthcare professionals to perform in their positions. Unlike conventional training approaches that stress time-based learning, competency-based training gives particular competency mastery first priority, therefore assuring that health

Training 130
article thumbnail

ESMO: AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases

Fierce Pharma

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients who have brain metastases.

Patients 301
article thumbnail

Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug

MedCity News

Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera. The post Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug appeared first on MedCity News.

article thumbnail

How Lilly’s sustainability goals come face to face with massive growth

PharmaVoice

Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.

200
200
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

AI-Powered chest X-Rays detect lung cancer early

PharmaTimes

New evidence highlights AI’s potential in early lung cancer detection

122
122
article thumbnail

ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals

Fierce Pharma

ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals kdunleavy Fri, 09/13/2024 - 07:38

299
299
article thumbnail

Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier

MedCity News

Some of the most difficult processes for digital health startups to navigate are those related to reimbursement and coding. Startups will often need to create entirely new codes for their products, so they should start thinking about this sooner rather than later, experts said at a recent conference. The post Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier appeared first on MedCity News.

311
311
article thumbnail

Meet MILTON, AZ's AI that can predict 1,000+ diseases

pharmaphorum

A machine-learning tool developed by AstraZeneca and trained on UK Biobank data, called MILTON, can predict over 1,000 diseases, before diagnosis

Training 122
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten